Eyepoint Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]
EyePoint, Inc. (EYPT)
Last eyepoint, inc. earnings: 3/5 07:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
expects top-line Phase 3 wet AMD data beginning in mid-2026, positioning DURAVYU as a potential six-month intravitreal treatment with a multi-MOA (VEGF/PDGF/IL-6 via JAK1) profile. Safety profile and monitoring: Across ~190 patients in prior studies the company reports no new safety signals, low intraocular inflammation (~1%), and cataract/floaters rates comparable to control, with ongoing internal masked reviews and independent DMC oversight. Financials and runway: Year-end cash and investments were $306 million (after a $173M October financing), which management says funds operations into Q4 2027, but 2025 revenues fell and operating expenses rose materially due to Phase 3 activity, widening the net loss. Interested in Eyepoint Pharmaceuticals, Inc.? Here are five stocks we like better. Breakout Momentum Plays You May Not Know About Eyepoint Pharmaceuticals (NASDAQ:EYPT) outlined late-stage clinical progress for its lead retinal candidate DURAVYU and reviewed fourth-quarte
Show less
Read more
Impact Snapshot
Event Time:
EYPT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EYPT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EYPT alerts
High impacting EyePoint, Inc. news events
Weekly update
A roundup of the hottest topics
EYPT
News
- Eyepoint Pharmaceuticals (EYPT) had its price target raised by HC Wainwright from $23.00 to $30.00. They now have a "buy" rating on the stock.MarketBeat
- EyePoint Inc (EYPT) Q4 2025 Earnings Call Highlights: Navigating Revenue Decline Amid Promising ... [Yahoo! Finance]Yahoo! Finance
- Eyepoint Pharmaceuticals (EYPT) had its price target raised by Chardan Capital from $27.00 to $29.00. They now have a "buy" rating on the stock.MarketBeat
- EyePoint Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]Yahoo! Finance
- EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments [Yahoo! Finance]Yahoo! Finance
EYPT
Earnings
- 3/4/26 - Miss
EYPT
Analyst Actions
- 3/4/26 - Chardan Capital
EYPT
Sec Filings
- 3/5/26 - Form 10-K
- 3/5/26 - Form 4
- 3/4/26 - Form 8-K
- EYPT's page on the SEC website